Rezolute Inc's stock has dropped by 89.40% in pre-market trading, crossing below its 5-day SMA. This drastic decline comes as the broader market shows signs of weakness, with the Nasdaq-100 down 0.44% and the S&P 500 down 0.83%.
The significant drop in Rezolute's stock price is attributed to broad market weakness, as the overall sentiment in the market has shifted negatively. The stock's movement below the 5-day SMA indicates a bearish trend, reflecting investor concerns amid the declining indices.
This decline raises questions about the company's future performance and investor confidence, especially in a challenging market environment. Investors will be closely monitoring any developments that could impact Rezolute's position in the market.
Wall Street analysts forecast RZLT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RZLT is 6.29 USD with a low forecast of 2.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Analyst Rating
Wall Street analysts forecast RZLT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RZLT is 6.29 USD with a low forecast of 2.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
4 Hold
0 Sell
Moderate Buy
Current: 3.380
Low
2.00
Averages
6.29
High
20.00
Current: 3.380
Low
2.00
Averages
6.29
High
20.00
Wedbush
Neutral
maintain
$1 -> $2
2026-01-08
Reason
Wedbush
Price Target
$1 -> $2
AI Analysis
2026-01-08
maintain
Neutral
Reason
Wedbush raised the firm's price target on Rezolute to $2 from $1 and keeps a Neutral rating on the shares. The firm notes the company reported PK/PD data and detailed glycemic control outcomes from the Phase 3 sunRIZE study of ersodetug in congenital hyperinsulinism. Wedbush believes that the new data demonstrates ersodetug's activity in modulating insulin receptors to reduce both events and time in hypoglycemia in treated patients, although whether the magnitude of benefit is sufficient to support an FDA approval remains unclear.
Guggenheim
Buy
downgrade
$15 -> $6
2025-12-12
Reason
Guggenheim
Price Target
$15 -> $6
2025-12-12
downgrade
Buy
Reason
Guggenheim lowered the firm's price target on Rezolute to $6 from $15 and keeps a Buy rating on the shares. Following the failure of the sunRIZE trial, the firm is eliminating cHI from its model despite managment's "optimism" on a potential path forward, the analyst tells investors. The firm's lower target reflects the elimination of cHI, a lower price point forecast for tHI and lower odds of success, until proven otherwise, for tHI, the analyst noted.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for RZLT
Unlock Now
Maxim
Jason McCarthy
Buy
downgrade
$20 -> $4
2025-12-12
Reason
Maxim
Jason McCarthy
Price Target
$20 -> $4
2025-12-12
downgrade
Buy
Reason
Maxim analyst Jason McCarthy lowered the firm's price target on Rezolute to $4 from $20 but keeps a Buy rating on the shares. The firm cites the company's Phase 3 sunRIZE study of ersodetug in congenital hyperinsulinism, which did not meet its primary or secondary endpoint. The miss is clearly disappointing, but it may not tell the complete story as there are several nuances to consider, including the viability of a randomized controlled trial in ultra-rare disease, the use of background therapy for CHI in the trial and that the 59 patients that completed the study, the analyst tells investors in a research note.
H.C. Wainwright
Douglas Tsao
Buy
downgrade
$14 -> $5
2025-12-12
Reason
H.C. Wainwright
Douglas Tsao
Price Target
$14 -> $5
2025-12-12
downgrade
Buy
Reason
H.C. Wainwright analyst Douglas Tsao lowered the firm's price target on Rezolute to $5 from $14 and keeps a Buy rating on the shares. The firm is "surprised and disappointed "by the negative results of the sunRIZE study, but it still sees a path forward. The analyst continues to see value in the shares and pushed out the launch of ersodetug in congenital hyperinsulinism from 2027 to 2028.
About RZLT
Rezolute, Inc. is a late-stage rare disease company, which is focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI). Its lead clinical asset, Ersodetug (formerly RZ358), is a potential treatment for hypoglycemia caused by multiple forms of hyperinsulinism including congenital HI and tumor HI. Ersodetug is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat, and muscle. Congenital is a rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas. RZ402, which is an oral plasma kallikrein inhibitor (PKI) being developed as a potential therapy for the chronic treatment of diabetic macular edema (DME). DME is a vascular complication of diabetes and a leading cause of blindness. RZ402 is designed to block bradykinin production and its resulting effects on vascular leakage and inflammation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
